Trial Profile
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs ONC-206 (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; CNS cancer; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Medulloblastoma; Meningioma; Neuroectodermal tumours; Neuroepithelial neoplasms; Oligodendroglioma; Primitive neuroectodermal tumours; Sarcoma; Tumours
- Focus Adverse reactions; First in man
- Sponsors Chimerix; Oncoceutics
- 01 Mar 2024 According to a Chimerix media release, the company expects to report preliminary safety and pharmacokinetic data from these trials beginning in mid-2024.
- 01 Mar 2024 According to a Chimerix media release, the company is planning in completing ONC206 dose escalation this year
- 04 May 2023 According to a Chimerix media release, the company expects to complet dose escalation by first half of 2024,